Aerovate Therapeutics Past Earnings Performance
Past criteria checks 0/6
Aerovate Therapeutics's earnings have been declining at an average annual rate of -46.8%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-46.8%
Earnings growth rate
68.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -105.1% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Here's Why Aerovate Therapeutics (NASDAQ:AVTE) Must Use Its Cash Wisely
Oct 01
Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market
Jun 11Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation
May 24Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
Feb 09We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate
Oct 17Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
Jul 04Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans
Feb 28A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Jan 06Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth
Oct 14Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation
Jul 01We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth
Jan 22Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth
Sep 30Revenue & Expenses Breakdown
How Aerovate Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -85 | 21 | 69 |
| 30 Jun 24 | 0 | -88 | 18 | 76 |
| 31 Mar 24 | 0 | -82 | 18 | 71 |
| 31 Dec 23 | 0 | -76 | 17 | 64 |
| 30 Sep 23 | 0 | -70 | 17 | 59 |
| 30 Jun 23 | 0 | -64 | 15 | 53 |
| 31 Mar 23 | 0 | -57 | 15 | 45 |
| 31 Dec 22 | 0 | -52 | 15 | 39 |
| 30 Sep 22 | 0 | -45 | 14 | 31 |
| 30 Jun 22 | 0 | -37 | 14 | 24 |
| 31 Mar 22 | 0 | -31 | 11 | 20 |
| 31 Dec 21 | 0 | -23 | 8 | 15 |
| 30 Sep 21 | 0 | -18 | 5 | 13 |
| 30 Jun 21 | 0 | -15 | 3 | 12 |
| 31 Mar 21 | 0 | -11 | 1 | 9 |
| 31 Dec 20 | 0 | -10 | 1 | 8 |
Quality Earnings: AVTE is currently unprofitable.
Growing Profit Margin: AVTE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AVTE is unprofitable, and losses have increased over the past 5 years at a rate of 46.8% per year.
Accelerating Growth: Unable to compare AVTE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVTE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: AVTE has a negative Return on Equity (-105.12%), as it is currently unprofitable.